Volpara share price leaps 5% following record cash receipts

Volpara's results appeared to impress investors today.

| More on:
Four people on the beach leap high into the air.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Volpara shares are lifting on the ASX today 
  • The health technology company reported 'record' quarterly cash receipts from customers 
  • A strategy to return to profit by FY25 was also delivered to the market 

The Volpara Health Technologies Ltd (ASX: VHT) share price is rising today after the company released its quarterly results.

The company's shares lifted 13% in earlier trade before retreating. The Volpara share price is now up 4.65%, trading at 67.5 cents.

Volpara develops software for the early detection of breast cancer. Let's take a look at what Volpara reported in today's results.

Volpara share price responds to 'strong' update

The Q1 FY23 quarterly cash flow report is likely driving the Volpara share price higher today. Highlights include:

  • Customer cash receipts up 35% on Q1 FY22 to NZ $8.7 million
  • Net operating and investing cash outflow of NZ$3.6 million, compared to N$2.9 million in the previous quarter
  • Subscription receipts lifted 36% on prior corresponding quarter to NZ$8.3 million
  • Net cash at hand of NZ$15.2 million. A $10 million undrawn bank facility is also available
  • Guidance of NZ$31.5 to $33 million revenue in FY23

What else did Volpara report?

Volpara said cash receipts were the "strongest on record".

Net outflow was 24% on the previous quarter, due to multiple costs, including performance-related pay. Volpara was expecting this loss but plans to reduce outflows from Q3 onwards.

Volpara described its cash position as "strong" and highlighted it has no debt. Management is confident the cash at hand will help the company break even in the future.

Highlights for the quarter included a partnership with Microsoft, and a 'best scientific contribution' award for a scientific paper.

Contracted annual recurring revenue (CARR) lifted by US$1.5 million on the prior quarter to US$23.7 million.

Annual recurring revenue (ARR) also lifted by $1.2 million to US$18.5 million.

Management commentary

Speaking on the results that are giving the Volpara share price a boost today, CEO Teri Thomas said:

This quarter we are pleased with our continued growth. We are delighted about the momentum we've gained with large healthcare organisations' faith in us and our portfolio of products and services.

We are highly focused on continued support of our customers' successes, while engaging with additional 'elephant-sized' organisations for the next quarters

Strategy update

Volpara is aiming to return to profit by FY25 and balance the books by Q4 FY24. Central to this return to profit will be focussing on high revenue geographic regions, including Australia and the United States.

The company said it will prioritise sales opportunities that generate high value, and large revenue. Volpara will also keep investing in science and technology.

Commenting on this strategy, Thomas said: "This time focusing our expertise in both the products and geographical areas that provide maximum value to shareholders will position us well for growth as a profitable company within the foreseeable future."

Volpara will also freeze or limit investment in low-margin or long lead time products.

Volpara share price snapshot

The Volpara share price has lost 38% in the past year and more than 34% year to date.

However, in the past month, the company's stock has exploded 69%.

Volpara has a market capitalisation of about $173 million based on today's share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended VOLPARA FPO NZ. The Motley Fool Australia has positions in and has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »